Accuray Incorporated (NASDAQ:ARAY) Stock Holdings Lowered by Perritt Capital Management Inc

Perritt Capital Management Inc reduced its holdings in Accuray Incorporated (NASDAQ:ARAY) by 20.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,000 shares of the medical equipment provider’s stock after selling 25,000 shares during the period. Perritt Capital Management Inc’s holdings in Accuray were worth $188,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Accuray by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock valued at $4,329,000 after buying an additional 6,758 shares during the last quarter. Heartland Advisors Inc. raised its stake in shares of Accuray by 14.1% during the fourth quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider’s stock worth $7,573,000 after buying an additional 472,800 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Accuray by 482.4% during the fourth quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 201,037 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Accuray in the 4th quarter valued at $43,000. Finally, Perkins Capital Management Inc. raised its holdings in Accuray by 18.3% during the 4th quarter. Perkins Capital Management Inc. now owns 68,000 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 10,500 shares during the period. 64.08% of the stock is owned by institutional investors and hedge funds.

Accuray Stock Down 0.6 %

Shares of NASDAQ ARAY opened at $1.78 on Wednesday. The company has a market cap of $183.04 million, a price-to-earnings ratio of -35.60 and a beta of 1.46. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $2.95. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The stock has a 50-day moving average price of $2.08 and a two-hundred day moving average price of $1.98.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. As a group, analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research report on Saturday.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.